Bayer Reports US FDA sNDA Acceptance for Kerendia to Treat Non-Diabetic CKD 

Shots: The US FDA has accepted sNDA of Kerendia (finerenone) for the treatment of adults with chronic kidney disease (CKD) without diabetes sNDA was supported by the P-III (FIND-CKD) trial assessing Kerendia (10 or 20mg) vs PBO, both on top of maximum tolerated labeled doses of a RAS-blocking therapy, in >1,500 adults with non-diabetic CKD  Trial showed slowed kidney disease progression, reducing the annual eGFR decline by 0.7 mL/min/1.73 m²/year over 32mos. It also reduced the risk of the key CV-kidney composite outcome by 23%, with other 2EPs supporting its overall positive profile Ref: Businesswire |   Image: Bayer  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Bayer Reports US FDA sNDA Acceptance for Kerendia to Treat Non-Diabetic CKD  appeared first on PharmaShots.